D-Amino acid oxidase knockdown in the mouse cerebellum reduces NR2A mRNA

Molecular and Cellular Neuroscience

Volumn 46, Issue 1, 2011, Pages 167-175

  Burnet, Philip W J ^a   Anderson, Patrick N ^b   Chen, Li ^a   Nikiforova, Natalia ^c   Harrison, Paul J ^a   Wood, Matthew J A ^c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

C6 glioma; Cerebellum; D Amino acid oxidase; Lentivirus; NMDA receptor; RNA interference; ShRNA; Western blot

Indexed keywords

DEXTRO AMINO ACID OXIDASE; MESSENGER RNA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; SHORT HAIRPIN RNA;

ANIMAL CELL; ARTICLE; CEREBELLUM; CONTROLLED STUDY; IMMUNOREACTIVITY; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RNA INTERFERENCE;

ANIMALS; CELL LINE; CEREBELLUM; D-AMINO-ACID OXIDASE; GENE KNOCKDOWN TECHNIQUES; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; LENTIVIRUS; MALE; MENTAL DISORDERS; MICE; MICE, INBRED C57BL; PROTEIN SUBUNITS; RATS; RECEPTORS, N-METHYL-D-ASPARTATE; RNA INTERFERENCE; RNA, MESSENGER; SERINE;

LENTIVIRUS;

EID: 78650856866     PISSN: 10447431     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcn.2010.08.018     Document Type: Article

References (48)

1. Almond S.L., Fradley R.L., Armstrong E.J., Heavens R.B., Rutter A.R., Newman R.J., Chiu C.S., Konno R., Hutson P.H., Brandon N.J. Behavioral and biochemical characterization of a mutant mouse strain lacking d-amino acid oxidase activity and its implications for schizophrenia. Mol. Cell. Neurosci. 2006, 32:324-334.
2. Bidoret C., Ayon A., Barbour B., Casado M. Presynaptic NR2A-containing NMDA receptors implement a high-pass filter synaptic plasticity rule. Proc. Natl Acad. Sci. USA 2009, 106:14126-14131.
3. Burnet P.W., Hutchinson L., von Hesling M., Gilbert E.J., Brandon N.J., Rutter A.R., Hutson P.H., Harrison P.J. Expression of d-serine and glycine transporters in the prefrontal cortex and cerebellum in schizophrenia. Schizophr. Res. 2008, 102:283-294.
4. Burnet P.W., Eastwood S.L., Bristow G.C., Godlewska B.R., Sikka P., Walker M., Harrison P.J. d-Amino acid oxidase activity and expression are increased in schizophrenia. Mol. Psychiatry 2008, 13:658-660.
5. Cebers G., Cebere A., Kovács A.D., Högberg H., Moreira T., Liljequist S. Increased ambient glutamate concentration alters the expression of NMDA receptor subunits in cerebellar granule neurons. Neurochem. Int. 2001, 39:151-160.
6. Chen B.S., Braud S., Badger J.D., Isaac J.T., Roche K.W. Regulation of NR1/NR2C N-methyl-d-aspartate (NMDA) receptors by phosphorylation. J. Biol. Chem. 2006, 281:16583-16590.
7. Chen P.E., Geballe M.T., Katz E., Erreger K., Livesey M.R., O'Toole K.K., Le P., Lee C.J., Snyder J.P., Traynelis S.F., Wyllie D.J. Modulation of glycine potency in rat recombinant NMDA receptors containing chimeric NR2A/2D subunits expressed in Xenopus laevis oocytes. J. Physiol. 2008, 586:227-245.
8. Colin A., Faideau M., Dufour N., Auregan G., Hassig R., Andrieu T., Brouillet E., Hantraye P., Bonvento G., Déglon N. Engineered lentiviral vector targeting astrocytes in vivo. Glia 2009, 57:667-679.
9. Croci C., Fasano S., Superchi D., Perani L., Martellosio A., Brambilla R., Consalez G., Bongarzone E.R. Cerebellar neurons and glial cells are transducible by lentiviral vectors without decrease of cerebellar functions. Dev. Neurosci. 2006, 28:216-221.
10. Coyle J.T., Tsai G., Goff D. Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia. Ann. NY Acad. Sci. 2003, 1003:318-327.
11. Danos O. AAV vectors for RNA-based modulation of gene expression. Gene Ther. 2008, 15:864-869.
12. Déglon N., Tseng J.L., Bensadoun J.C., Zurn A.D., Arsenijevic Y., Pereira de Almeida L., Zufferey R., Trono D., Aebischer P. Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson's disease. Hum. Gene Ther. 2000, 11(1):179-190. 2000 Jan 1.
13. Duplantier A.J., Becker S.L., Bohanon M.J., Borzilleri K.A., Chrunyk B.A., Downs J.T., Hu L.Y., El-Kattan A., James L.C., Liu S., et al. Discovery, SAR, and pharmacokinetics of a novel 3-hydroxyquinolin-2(1H)-one series of potent d-amino acid oxidase (DAAO) inhibitors. J. Med. Chem. 2009, 52:3576-3585.
14. Eastwood S.L., Lyon L., George L., Andrieux A., Job D., Harrison P.J. Altered expression of synaptic protein mRNAs in STOP (MAP6) mutant mice. J. Psychopharmacol. 2007, 21:635-644.
15. Ehlert E.M., Eggers R., Niclou S.P., Verhaagen J. Cellular toxicity following application of adeno-associated viral vector-mediated RNA interference in the nervous system. BMC Neurosci. 2010, 11:20.
16. Hamase K., Konno R., Morikawa A., Zaitsu K. Sensitive determination of d-amino acids in mammals and the effect of d-amino-acid oxidase activity on their amounts. Biol. Pharm. Bull. 2005, 28:1578-1584.
17. Harrison P.J., Weinberger D.R. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol. Psychiatry 2005, 10:40-68. [Erratum in: Mol Psychiatry. (2005) 10:420. Mol Psychiatry. (2005) 10:804.].
18. Hashimoto A., Konno R., Yano H., Yoshikawa M., Tamaki R., Matsumoto H., Kobayashi H. Mice lacking d-amino acid oxidase activity exhibit marked reduction of methamphetamine-induced stereotypy. Eur. J. Pharmacol. 2008, 586:221-225.
19. Hoyer D. RNA interference for studying the molecular basis of neuropsychiatric disorders. Curr. Opin. Drug Discov. Devel. 2007, 10:122-129.
20. Hirai H. Progress in transduction of cerebellar Purkinje cells in vivo using viral vectors. Cerebellum 2008, 7:273-278.
21. Hirano T., Watanabe D., Kawaguchi S.Y., Pastan I., Nakanishi S. Roles of inhibitory interneurons in the cerebellar cortex. Ann. NY Acad. Sci. 2002, 978:405-412.
22. Iizuka A., Takayama K., Torashima T., Yamasaki M., Koyama C., Mitsumura K., Watanabe M., Hirai H. Lentiviral vector-mediated rescue of motor behavior in spontaneously occurring hereditary ataxic mice. Neurobiol. Dis. 2009, 35:457-465.
23. Labrie V., Duffy S., Wei W., Barger S., Baker G.B., Roder J.C. Genetic inactivation of d-amino acid oxidase enhances extinction and reversal learning in mice. Learn. Mem. 2008, 16:28-37.
24. Laflamme M., Robichaud G.A. Gene suppression technologies in high-throughput analysis: front- and back-side applications. OMICS 2007, 11:129-142.
25. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25:402-408.
26. Llansola M., Sanchez-Perez A., Cauli O., Felipo V. Modulation of NMDA receptors in the cerebellum. 1. Properties of the NMDA receptor that modulate its function. Cerebellum 2005, 4:154-161.
27. Lundberg C., Björklund T., Carlsson T., Jakobsson J., Hantraye P., Déglon N., Kirik D. Applications of lentiviral vectors for biology and gene therapy of neurological disorders. Curr. Gene Ther. 2008, 8:461-473.
28. Madeira C., Freitas M.E., Vargas-Lopes C., Wolosker H., Panizzutti R. Increased brain d-amino acid oxidase (DAAO) activity in schizophrenia. Schizophr. Res. 2008, 101:76-83.
29. McBride J.L., Boudreau R.L., Harper S.Q., Staber P.D., Monteys A.M., Martins I., Gilmore B.L., Burstein H., Peluso R.W., Polisky B., Carter B.J., Davidson B.L. Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc. Natl Acad. Sci. USA 2008, 105:5868-5873.
30. Morikawa A., Hamase K., Inoue T., Konno R., Zaitsu K. Alterations in d-amino acid levels in the brains of mice and rats after the administration of d-amino acids. Amino Acids 2007, 32:13-20.
31. Ono K., Shishido Y., Park H.K., Kawazoe T., Iwana S., Chung S.P., Abou El-Magd R.M., Yorita K., Okano M., Watanabe T., Sano N., Bando Y., Arima K., Sakai T., Fukui K. Potential pathophysiological role of d-amino acid oxidase in schizophrenia: immunohistochemical and in situ hybridization study of the expression in human and rat brain. J. Neural Transm. 2009, 116:1335-1347.
32. Park H.K., Shishido Y., Ichise-Shishido S., Kawazoe T., Ono K., Iwana S., Tomita Y., Yorita K., Sakai T., Fukui K. Potential role for astroglial d-amino acid oxidase in extracellular d-serine metabolism and cytotoxicity. J. Biochem. 2006, 139:295-304.
33. Petersen R.C., Stillman R.C. Phencyclidine: an overview. NIDA Res. Monogr. 1978, 21:1-17.
34. Resink A., Villa M., Benke D., Hidaka H., Möhler H., Balázs R. Characterization of agonist-induced down-regulation of NMDA receptors in cerebellar granule cell cultures. J. Neurochem. 1996, 66:369-377.
35. Saigoh K., Matsui K., Takahashi K., Nishikawa T., Wada K. The stereo-specific effect of d-serine ethylester and the d-cycloserine in ataxic mutant mice. Brain Res. 1998, 808:42-47.
36. Sibley C.R., Seow Y., Wood M.J. Novel RNA-based strategies for therapeutic gene silencing. Mol. Ther. 2010, 18:466-476.
37. Sikka P., Walker R., Cockayne R., Wood M.J., Harrison P.J., Burnet P.W. d-Serine metabolism in C6 glioma cells: involvement of alanine-serine-cysteine transporter (ASCT2) and serine racemase (SRR) but not d-amino acid oxidase (DAO). J. Neurosci. Res. 2010, 88:1829-1840.
38. Torashima T., Yamada N., Itoh M., Yamamoto A., Hirai H. Exposure of lentiviral vectors to subneutral pH shifts the tropism from Purkinje cell to Bergmann glia. Eur. J. Neurosci. 2006, 24:371-380.
39. Torashima T., Koyama C., Iizuka A., Mitsumura K., Takayama K., Yanagi S., Oue M., Yamaguchi H., Hirai H. Lentivector-mediated rescue from cerebellar ataxia in a mouse model of spinocerebellar ataxia. EMBO Rep. 2008, 9:393-399.
40. Tsai G., Yang P., Chung L.C., Lange N., Coyle J.T. d-Serine added to antipsychotics for the treatment of schizophrenia. Biol. Psychiatry 1998, 44:1081-1089.
41. Ulusoy A., Sahin G., Björklund T., Aebischer P., Kirik D. Dose optimization for long-term rAAV-mediated RNA interference in the nigrostriatal projection neurons. Mol. Ther. 2009, 17:1574-1584.
42. Verrall L., Walker M., Rawlings N., Benzel I., Kew J.N., Harrison P.J., Burnet P.W. d-Amino acid oxidase and serine racemase in human brain: normal distribution and altered expression in schizophrenia. Eur. J. Neurosci. 2007, 26:1657-1669.
43. Verrall L., Burnet P.W., Betts J.F., Harrison P.J. The neurobiology of d-amino acid oxidase and its involvement in schizophrenia. Mol. Psychiatry 2010, 15:122-137.
44. Vidalin O., Muslmani M., Estienne C., Echchakir H., Abina A.M. In vivo target validation using gene invalidation, RNA interference and protein functional knockout models: it is the time to combine. Curr. Opin. Pharmacol. 2009, 9:669-676.
45. Wang L.Z., Zhu X.Z. Spatiotemporal relationships among d-serine, serine racemase, and d-amino acid oxidase during mouse postnatal development. Acta Pharmacol. Sin. 2003, 24:965-974.
46. White M.D., Farmer M., Mirabile I., Brandner S., Collinge J., Mallucci G.R. Single treatment with RNAi against prion protein rescues early neuronal dysfunction and prolongs survival in mice with prion disease. Proc. Natl Acad. Sci. USA 2008, 105:10238-10243.
47. Willetts J., Balster R.L., Leander J.D. The behavioral pharmacology of NMDA receptor antagonists. Trends Pharmacol. Sci. 1990, 10:423-428.
48. Williams S.M., Diaz C.M., Macnab L.T., Sullivan R.K., Pow D.V. Immunocytochemical analysis of d-serine distribution in the mammalian brain reveals novel anatomical compartmentalizations in glia and neurons. Glia 2006, 53:401-411.